This study demonstrates the efficacy and safety of another 5-ASA agent in a delayed response form embedded in a hydrophobic-hydrophilic structure. Original Article Kamm MA, Sandborn WJ, Gassull M, et al. Once-daily, high-concentration MMX mesalamine in active ulcerative colitis. Gastroenterology. 2007;132(1):66–75.

